SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Quantum BioPharma Ltd. QNTM NASDAQ

NASDAQ Global Market • Healthcare • Drug Manufacturers - Specialty & Generic • CA • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Quantum BioPharma Ltd. (QNTM) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $3.07. It has a SharesGrow Score of 36/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Valuation: QNTM trades at a trailing Price-to-Earnings (P/E) of -0.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.

Net income is $27M (loss), growing at -14.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $2M against $7M equity (Debt-to-Equity (D/E) ratio 0.27, conservative). Current ratio is 1.07 (adequate). Debt-to-assets is 16.8%. Total assets: $11M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

QNTM SharesGrow Score Overview

48/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — QNTM

QNTM trades at a trailing Price-to-Earnings (P/E) of -0.5 (S&P 500 average ~25). Forward PEG 0.01 — Peter Lynch undervalued (≤1.0). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

QNTM: +0%/yr revenue is, -14.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet QNTM: Debt-to-Equity (D/E) ratio 0.27 (conservative), Current ratio is 1.07 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

QNTM: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range2.07-38.25

Volume207.77K

Avg Volume (30D)319.51K

Market Cap$12.64M

Beta (1Y)0.32

Share Statistics

EPS (TTM)-8.11

Shares Outstanding$3.29M

IPO Date2018-06-08

CEOLakshmi Kotra

Financial Highlights & Ratios

Gross Profit$-555.33K

EBITDA$-15.03M

Net Income$-26.63M

Operating Income$-15.59M

Total Cash$6.17M

Total Debt$1.87M

Net Debt$-29.09K

Total Assets$11.14M

Price / Earnings (P/E)-0.4

Analyst Forecast

Company Info

CountryCA

ExchangeNASDAQ Global Market

CurrencyUSD

ISINCA74764Y2050

Price Chart

QNTM

Quantum BioPharma Ltd. ↗ · NASDAQ Global Market

Healthcare • Drug Manufacturers - Specialty & Generic

2.07 52WK RANGE 38.25

People Also View

Rein Therapeutics Inc.

Cumberland Pharmaceuticals Inc.

Actinium Pharmaceuticals, Inc.

Rockwell Medical, Inc.

Annovis Bio, Inc.

Celularity Inc.

Evaxion Biotech A/S

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message